NORCROSS, Ga. … Novoste (NASDAQ: NOVT), which develops advanced medical treatments for coronary and vascular diseases, has promoted Andrew M. Green to the position of vice president of regulatory and clinical affairs.

Green will report to President and Chief Executive Alfred J. Novak and will continue to be responsible for the regulatory affairs department and will also be responsible for the strategic direction and day-to-day operations of the clinical affairs department.

“Drew has played a pivotal leadership role in bringing Novoste’s brachytherapy products to market worldwide, building an effective regulatory staff and helping to direct the company in selecting new clinical opportunities,” Novak said in a statement. “In addition to his regulatory background, Drew’s experience in clinical trial development and analysis for the FDA and Novoste will help position us to complete our current clinical trials.”

Since joining Novoste in 1996, Green has held several positions in the regulatory affairs group and was promoted to vice president in July 2002. From 1994 to 1996, Green served as scientific reviewer for the U.S. Food and Drug Administration, where he reviewed scientific, technical, pre-clinical and clinical data submitted in support of safety and effectiveness of interventional cardiology medical devices.